Dr. Washington Loses DEA Privileges After State License Revocation
Published Date: 7/8/2025
Notice
Summary
Dr. William Washington lost his medical license in Washington state, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final and immediate. This means Dr. Washington can no longer legally prescribe or manage controlled drugs, effective right now.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Washington
The DEA revoked William Washington, M.D.'s Certificate of Registration No. FW5625213, so he can no longer legally prescribe, dispense, or handle controlled substances. The Washington medical license was permanently revoked on November 26, 2024, an Order to Show Cause was served January 22, 2025, and the DEA Order revoking the DEA registration is effective August 7, 2025.
Pending DEA Applications Denied
The DEA denied any pending applications of William Washington, M.D., to renew or modify Certificate of Registration No. FW5625213 and denied any other pending application for additional registration in Washington. That denial is part of the Order effective August 7, 2025.
Fifteen-Day Reconsideration Right
The registrant may file a properly supported motion for reconsideration of the factual finding that he is not licensed to practice medicine in Washington within fifteen calendar days of the date of this Order. Any such motion and response must be filed and served by email to the other party and to the DEA Office of the Administrator at [email protected].
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-12607, Bayer CropScience: Availability of a Petition for a Determination of Nonregulated Status and Draft Plant Pest Risk Assessment for MON 95275 Maize (Corn)
Bayer CropScience wants permission to grow a new type of corn called MON 95275 that protects itself from pesky corn rootworms using special proteins. The government is sharing the petition and a safety check for everyone to review and comment on. Farmers, consumers, and anyone interested can weigh in before a final decision is made, which could change how corn is grown and protected.
Next: 2025-12609, Tanya Newlove, N.P.; Decision and Order
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.